Oxford Immunotec Global PLC, a diagnostics company with U.S. headquarters in Marlborough, announced revenue and profit growth in the first quarter of 2015.
The company saw revenue, $13.8 million, grow by 12 percent led by the U.S. and Asia markets. U.S. revenue was $6.4 million in the first quarter of 2015 representing 27 percent growth, due to expanding the company’s customer base, over revenue of $5 million in the same period in 2014. Asia revenue was $5.7 million in the first quarter of 2015 representing five percent growth over first quarter revenue of $5.4 million in 2014.
“Our sales performance came in above our expectations led by strong growth in the U.S. and Asia,” Peter Wrighton-Smith, CEO of Oxford Immunotec, said in a statement.
Gross profit for the first quarter of 2015 was $7.1 million, an increase of $884,000 over gross profit of $6.3 million in the same period of 2014.
